Trial of Weekly Taxotere and Irinotecan (CPT-11) in Patients With Advanced Non-small Cell Lung Cancer

Part of paid clinical trials in Bridgewater, New Jersey.

Sponsor
Sanofi
Study ID
NCT00819728
Phase
PHASE2
Status
Completed

Conditions

  • Carcinoma, Non-Small-Cell Lung

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Docetaxel — DRUG
    35mg/m2 IV each week for 4 weeks
  • Irinotecan — DRUG
    50mg/m2 IV each week for 4 weeks

Study Details

The main purpose of the study is to determine the activity of the weekly combination of docetaxel (Taxotere) and irinotecan in terms of response rate in subjects with advanced, previously untreated, non-small cell lung cancer. It is also to determine the activity of this combination in terms of response duration, time to progression, median survival, overall survival, and percent one-year survival, as well as the side-effect and toxicity profile of weekly Taxotere and weekly irinotecan.

Key Dates

Start date
Jun 30, 2000
Status verified
Jan 2011
Completion
Jan 31, 2003

Study Design

Enrollment
35 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Taxotere/Irinotecan

Locations (1)

FacilityCityStateZIPSite coordinators
Sanofi-Aventis USBridgewaterNew Jersey08807-

Find similar trials in Bridgewater, NJ

By research site
Sanofi-Aventis US· Bridgewater, NJ

Related Studies